JP4455324B2 - 肝細胞癌の診断 - Google Patents

肝細胞癌の診断 Download PDF

Info

Publication number
JP4455324B2
JP4455324B2 JP2004507835A JP2004507835A JP4455324B2 JP 4455324 B2 JP4455324 B2 JP 4455324B2 JP 2004507835 A JP2004507835 A JP 2004507835A JP 2004507835 A JP2004507835 A JP 2004507835A JP 4455324 B2 JP4455324 B2 JP 4455324B2
Authority
JP
Japan
Prior art keywords
antibody
gpc3
fragment
sample
hcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004507835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526979A (ja
Inventor
フィルムス，ホルヘ
カプーロ，マリアーナ
Original Assignee
サニーブルック ヘルスサイエンス センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29584393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4455324(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サニーブルック ヘルスサイエンス センター filed Critical サニーブルック ヘルスサイエンス センター
Publication of JP2005526979A publication Critical patent/JP2005526979A/ja
Application granted granted Critical
Publication of JP4455324B2 publication Critical patent/JP4455324B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004507835A 2002-05-23 2003-05-22 肝細胞癌の診断 Expired - Lifetime JP4455324B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38234002P 2002-05-23 2002-05-23
PCT/CA2003/000752 WO2003100429A2 (fr) 2002-05-23 2003-05-22 Diagnostic de carcinome hepatocellulaire

Publications (2)

Publication Number Publication Date
JP2005526979A JP2005526979A (ja) 2005-09-08
JP4455324B2 true JP4455324B2 (ja) 2010-04-21

Family

ID=29584393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004507835A Expired - Lifetime JP4455324B2 (ja) 2002-05-23 2003-05-22 肝細胞癌の診断

Country Status (18)

Country Link
US (1) US7883853B2 (fr)
EP (1) EP1506406B1 (fr)
JP (1) JP4455324B2 (fr)
CN (1) CN100401068C (fr)
AT (1) ATE425461T1 (fr)
AU (1) AU2003229191B2 (fr)
BR (1) BRPI0311233B8 (fr)
CA (1) CA2482881C (fr)
DE (1) DE60326567D1 (fr)
ES (1) ES2324029T3 (fr)
HK (1) HK1074251A1 (fr)
IL (1) IL164848A0 (fr)
MX (1) MXPA04011132A (fr)
NZ (1) NZ536521A (fr)
PT (1) PT1506406E (fr)
RU (1) RU2319969C2 (fr)
WO (1) WO2003100429A2 (fr)
ZA (1) ZA200410077B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (fr) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Anticorps d'un peptide n-terminal du gpc3 solubilise dans le sang
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
AU2002328429A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
WO2004067571A1 (fr) * 2003-01-30 2004-08-12 Wu, Mengchao Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci
EP1671645A4 (fr) * 2003-09-04 2007-07-25 Chugai Pharmaceutical Co Ltd Remede et medicament de detection pour le cancer des voies biliaires
WO2005085861A2 (fr) * 2004-03-03 2005-09-15 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Acides nucleiques et polypeptides codes destines a etre utilises dans des troubles hepatiques et du cancer epithelial
JP4658926B2 (ja) 2004-04-28 2011-03-23 株式会社ペルセウスプロテオミクス 肝癌治療後の再発予測判定薬
NZ545720A (en) 2004-07-09 2010-01-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
KR20130103580A (ko) * 2004-08-24 2013-09-23 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
WO2006038588A1 (fr) * 2004-10-05 2006-04-13 Perseus Proteomics Inc. Médicament permettant de contrôler l'aggravation d'une hépatite
MX2007004593A (es) * 2004-10-26 2007-06-22 Chugai Pharmaceutical Co Ltd Anticuerpo anti-glipican 3 que tiene cadena de azucar modificada.
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007053659A2 (fr) * 2005-11-01 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede de criblage du carcinome hepatocellulaire
MX2010010136A (es) * 2008-03-17 2011-02-23 Univ Miyazaki Metodo para detectar celulas de cancer de higado usando anticuerpo anti-glipicano 3.
CN101393217B (zh) * 2008-09-27 2012-05-30 中国人民解放军第二军医大学 一种原发性肝癌血清标志物的检测试剂盒
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
WO2010098613A2 (fr) * 2009-02-27 2010-09-02 포항공과대학교 산학협력단 Composition pour le diagnostic du cancer du foie contenant tm7sf3 comme ingrédient actif, kit pour le diagnostic du cancer du foie contenant des anticorps anti-tm7sf3 comme ingrédient actif, et composition pharmaceutique pour prévenir ou pour traiter le cancer du foie
WO2010100862A1 (fr) 2009-03-05 2010-09-10 独立行政法人産業技術総合研究所 Procédé de détection et de détermination d'un cholangiocarcinome intrahépatique
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用
CN102183660A (zh) * 2011-03-09 2011-09-14 倪温慨 检测Glypican-3的时间分辨免疫荧光试剂盒
CN102353791A (zh) * 2011-06-30 2012-02-15 倪润洲 一种分离检测afp亚型的新方法
WO2015097928A1 (fr) 2013-12-24 2015-07-02 中外製薬株式会社 Méthode de mesure de protéine gpc3 soluble
EP4119947A1 (fr) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Médicament de ciblage gpc3 administré à un patient en réponse à une thérapie médicamenteuse de ciblage gpc3
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2014159087A1 (fr) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Immunoconjugés radiomarqués anti-glypican-3 pour l'imagerie imminuno-pet d'un carcinome hépatocellulaire
CN105452865A (zh) * 2013-08-06 2016-03-30 金弦起 小肝细胞癌和潜伏于肝硬化的肝细胞癌诊断用组合物
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
JP2017522861A (ja) * 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101704533B1 (ko) * 2014-10-13 2017-02-09 경북대학교병원 간암 바이오마커로서의 ＥＲＲγ 및 이의 용도
WO2017002934A1 (fr) 2015-07-01 2017-01-05 中外製薬株式会社 Agent thérapeutique à gpc3 ciblé administré à un patient dans lequel un agent thérapeutiques à gpc3 ciblé est déterminé comme étant efficace
DK3333192T3 (da) * 2015-08-03 2021-05-31 Cafa Therapeutics Ltd Antistof imod glypican-3 og anvendelse deraf
EP3428648B1 (fr) * 2016-03-10 2020-12-02 National Cancer Center Procédé d'aide à la prédiction d'un risque de récidive chez un patient atteint d'un carcinome hépatocellulaire, et utilisation d'un kit
EP4112641A1 (fr) 2016-03-15 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Procédés de traitement de cancers au moyen d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-gpc3
EP3684413A1 (fr) 2017-09-20 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Posologie pour polythérapie utilisant des antagonistes de liaison d'axe pd-1 et un agent de ciblage gpc3
AU2022388928A1 (en) 2021-11-16 2024-05-16 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171850A (en) * 1988-08-31 1992-12-15 The Ontario Cancer Institute Intestinal oncofetal gene
JP2946216B2 (ja) 1989-07-12 1999-09-06 武田薬品工業株式会社 新規ハイブリドーマ，モノクローナル抗体および用途
EP0477739A3 (en) * 1990-09-27 1992-12-09 F. Hoffmann-La Roche Ag Glycosyl-phosphatidylinositol-specific phospholipase d
WO1999037764A2 (fr) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Nouveaux membres de la famille des genes de glypicane
WO2000023109A1 (fr) * 1998-10-16 2000-04-27 The Regents Of The University Of California Glypicanes servant a detecter et a traiter le carcinome humain
AU2002315857B2 (en) * 2001-06-22 2007-07-26 Kaisha, Chugai Seiyaku Kabushiki Cell proliferation inhibitors containing anti-glypican 3 antibody

Also Published As

Publication number Publication date
BRPI0311233B1 (pt) 2019-08-13
JP2005526979A (ja) 2005-09-08
RU2004136285A (ru) 2005-10-10
MXPA04011132A (es) 2005-08-15
CN100401068C (zh) 2008-07-09
BRPI0311233A2 (pt) 2016-06-28
WO2003100429A3 (fr) 2004-02-19
US7883853B2 (en) 2011-02-08
HK1074251A1 (en) 2005-11-04
US20050233392A1 (en) 2005-10-20
EP1506406A2 (fr) 2005-02-16
ES2324029T3 (es) 2009-07-29
CA2482881A1 (fr) 2003-12-04
NZ536521A (en) 2006-04-28
IL164848A0 (en) 2005-12-18
ATE425461T1 (de) 2009-03-15
EP1506406B1 (fr) 2009-03-11
DE60326567D1 (de) 2009-04-23
ZA200410077B (en) 2005-12-28
AU2003229191B2 (en) 2009-07-30
PT1506406E (pt) 2009-06-03
BRPI0311233B8 (pt) 2021-07-27
RU2319969C2 (ru) 2008-03-20
WO2003100429A2 (fr) 2003-12-04
CA2482881C (fr) 2016-11-08
CN1653336A (zh) 2005-08-10
AU2003229191A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
JP4455324B2 (ja) 肝細胞癌の診断
US20200182878A1 (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
KR100768985B1 (ko) 조기암 종양 마커
US6835549B2 (en) Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma
Ofuji et al. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
WO2005043165A2 (fr) Methode specifique de detection du cancer
AU2015215008B2 (en) Composition and method for detecting malignant neoplastic disease
JP5229866B2 (ja) 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法
KR20050020806A (ko) 간세포암의 진단
IL164848A (en) Diagnosis of repatocellular carcinoma
JP2004198313A (ja) 甲状腺腫瘍の診断用キット
US20050272102A1 (en) Method for diagnosis of prostate cancer
US20240133889A1 (en) Use of he4 and other biochemical markers for assessment of ovarian cancers
JP5152766B2 (ja) 癌の浸潤と転移の検査方法及び検査用試薬
JP5429723B2 (ja) 大腸癌、動脈硬化症、又はメタボリックシンドロームの検出方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090814

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100106

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100203

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4455324

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140212

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term